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PromoterThe ﬁbrillins and latent transforming growth factor binding proteins (LTBPs) form a superfamily of extracellular
matrix (ECM) proteins characterized by the presence of a unique domain, the 8-cysteine transforming growth
factor beta (TGFβ) binding domain. These proteins are involved in the structure of the extracellular matrix and
controlling the bioavailability of TGFβ family members. Genes encoding these proteins show differential expres-
sion in mesenchymal cell types which synthesize the extracellular matrix. We have investigated the promoter
regions of the seven gene family members using the FANTOM5 CAGE database for human. While the protein
and nucleotide sequences show considerable sequence similarity, the promoter regions were quite diverse.
Most genes had a single predominant transcription start site region but LTBP1 and LTBP4 had two regions initiat-
ing different transcripts. Most of the family members were expressed in a range of mesenchymal and other cell
types, often associatedwith use of alternative promoters or transcription start siteswithin a promoter in different
cell types. FBN3was the lowest expressed gene, and was found only in embryonic and fetal tissues. The different
promoters for one gene were more similar to each other in expression than to promoters of the other family
members. Notably expression of all 22 LTBP2 promoters was tightly correlated and quite distinct from all other
family members. We located candidate enhancer regions likely to be involved in expression of the genes. Each
gene was associated with a unique subset of transcription factors across multiple promoters although several
motifs including MAZ, SP1, GTF2I and KLF4 showed overrepresentation across the gene family. FBN1 and FBN2,
which had similar expression patterns, were regulated by different transcription factors. This study highlights
the role of alternative transcription start sites in regulating the tissue speciﬁcity of closely related genes and
suggests that this important class of extracellular matrix proteins is subject to subtle regulatory variations that
explain the differential roles of members of this gene family.
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ghts reserved.1. Introduction
Vertebrate genomes containmany gene families, consisting of genes
with related sequence that arose through a range of duplication events
(reviewed by [1]). The existence of gene families can provide redundancy
and resilience to the genome, since one family member may substitute
(at least in part) for another which has been mutated. This has been
shown in knockout mouse models where a severe phenotype may only
be found when several family members are inactivated. For example,
several members of the SRC gene family had to be deleted to produce
a myeloid phenotype (reviewed by [2]). The presence of multiple ion
channel genes in the human genome led to the concept of repolarization
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sium, sodium and calcium ions in cardiacmyocytes, the heart beat can be
maintained even in the presence of onenon-functional protein [3,4]. Thus
mice homozygous for a deletion of the potassium channel gene Kcnd2
had no physiological or clinical phenotype, attributed to upregulation
of potassium ion channels encoded by the Kcna4 and Kcna5 genes [5].
The possibility that members of a gene family may be able to substitute
for each other has implications for genetically determined clinical condi-
tions. To assess overlapping roles it is important to understand the struc-
tural and functional relationships between gene family members. In this
study we have used the FANTOM5 promoter-based expression atlas
encompassing the largemajority of human cell types to examine promot-
er architecture and expression of members of the human ﬁbrillin/LTBP
gene family.
The ﬁbrillins and latent transforming growth factor binding proteins
(LTBPs) form a small family of extracellularmatrix (ECM) proteins char-
acterized by the presence of a unique domain, the transforming growth
factor beta (TGFβ) binding domain (TB domain) [6]. These proteins
consist primarily of repeated epidermal growth factor (EGF) domains,
most with the ability to bind calcium (Ca-EGF domains), interspersed
with TB domains (reviewed by [7]; see Fig. 1 of that paper). The family
members are important to both the structural integrity of the ECM and
the regulation of bioavailability of members of the TGFβ family of
growth factors. As well as being structurally similar, ﬁbrillins and
LTBPs appear to interact functionally in the sequestering and hence
inactivation of TGFβ family members [8].
In vertebrates, including eutherian, marsupial and monotreme
mammals, birds, reptiles and ﬁsh, ﬁbrillins are encoded by three
genes, FBN1, FBN2 and FBN3. In rats and mice the FBN3 gene appears
to have degenerated and does not produce a functional mRNA [9], but
in most mammals FBN3 is likely to be active since transcripts have
been detected (data from http://www.ensembl.org). There are a vari-
able number of annotated LTBP genes across species, from two in ﬁsh
to four in mammals: LTBP1, LTBP2, LTBP3 and LTBP4. It is possible that
one or more of the gene family members take over the role of FBN3 in
rats and mice.
Expression of ﬁbrillin/LTBP family members is principally found in
cells and tissues of mesenchymal origin. In mouse, Fbn1mRNA is ubiq-
uitous in mesenchymal cell types [10], whereas Fbn2 appears more
restricted in expression ([7]; see http://biogps.org, data for Fbn2). A
similar pattern was reported for human FBN2 [7]. Human FBN3 expres-
sion is restricted to embryonic/fetal tissues [9]. The LTBPs are also
expressed primarily in cell types of mesenchymal origin, particularly
osteoblasts and chondrocytes (http://biogps.org; [7]). This restricted
expression suggests that there may be common regulatory elements,
permissive for expression in mesenchymal cells, in the promoter
regions of the seven genes, with speciﬁc elements determining the pre-
cise cell types in which the gene is expressed.
Consistent with their function inmesenchymal cell types, mutations
inmembers of this gene superfamily result in phenotypes that primarily
affect connective tissue types (reviewed in [7]). Although some aspects
of the phenotypes overlap, each gene is associated with a unique spec-
trum of anomalies, reﬂecting the cell/tissue speciﬁc expression pattern
[7]. Understanding the relationships between the family members
and their differential regulation may lead to novel therapies in which
alternative genes are upregulated to compensate for the mutated gene
(as has been suggested for treatment of Duchenne muscular dystrophy
by upregulating the dystrophin paralogue utrophin [11]).
The FANTOM (Functional Annotation of Mammals) projects co-
ordinated by the RIKEN Institute in Japan have provided extensive
information on gene expression in human and mouse and allowed the
identiﬁcation and characterization of a large number of gene promoter
regions [12,13], using cap-selected 5′ end sequencing of mRNAs (cap
analysis of gene expression; CAGE). Promoters were described as
being sharp (with transcription initiating on a single base, usually asso-
ciated with a conventional TATA box) or broad (with transcriptioninitiating over a range of bases, usually associated with a CpG island).
Analysis of transcription start sites also showed that genes often have
alternative promoters which may have different expression proﬁles,
and may change the protein product of the gene by skipping initial
exons [14]. We previously used the results from the FANTOM3 project
to identify the promoter region of human and mouse FBN1 [15] and
FBN2 (unpublished). However those data included few tissues showing
expression of FBN3 in humans. The current FANTOM5 project involves
many more tissue and cell types likely to express members of the
ﬁbrillin and LTBP families [16].We have now taken advantage of the ex-
tensive information on gene expression, promoter usage and regulation
available through FANTOM5 to identify the promoter regions, possible
enhancer sequences and potential regulatory motifs for each of these
genes in human. We show that different promoters and enhancers
are used in a tissue-speciﬁc manner under differential regulation, with
predominant expression in a subset of mesenchymally derived cells
but additional expression in cells of neural, embryonic and other origins,
highlighting the varied roles of this gene family. This information
may lead to strategies for treatment of diseases that result from muta-
tion of these genes, such as Marfan syndrome (OMIM: 154700; FBN1
OMIM: 134797), congenital contractural arachnodactyly (OMIM:
121050; FBN2 OMIM: 612570), primary congenital glaucoma (OMIM:
613086; LTBP2 OMIM: 602091) and cutis laxa with severe systemic
abnormalities (OMIM: 613177; LTBP4 OMIM: 604710) [7].
This work is part of the FANTOM5 project. Data downloads, genomic
tools and co-published manuscripts have been summarized at http://
fantom.gsc.riken.jp/5/.
2. Methods
2.1. Cell lines and cell culture
Five human cell lines and a primary adult derived mesenchymal
stem cell culture were used to analyze expression patterns of ﬁbrillin/
LTBP gene family members. SAOS-2 (sarcoma osteogenic 2) is a
hypotriploid line derived from the osteosarcoma of an 11-year-old
Caucasian female and has been in culture since 1973 [17,18]. It retains
many of the characteristics of osteoblasts including the ability to
mineralize in the presence of phosphate molecules [18]. MG63 is a
hypotriploid line derived from the osteosarcoma of a 14-year-old
Caucasian male and has been in culture since 1977 [19,20]. This line
fails to mineralize under experimental conditions and may represent a
more immature, less osteoblastic cell line when compared to Saos-2
[21,22]. Saos-2 and MG63 cells were cultured in McCoys5A medium
(Gibco) with 10% heat inactivated fetal bovine serum, antibiotics and
antifungals. Normal human dermal ﬁbroblast (NHDF) cells, grown
from human circumcision material, were obtained from Dr Finn Grey,
Roslin Institute. The cells were cultured in DMEM with 10% non-heat
inactivated fetal bovine serum, antibiotics and antifungals. The cells
were removed from the ﬂasks with 1× Trypsin–EDTA solution (Sigma).
All cell lines were seeded at approximately 25% of conﬂuence and proc-
essed for RNA extraction at two days after plating for the osteosarcoma
cell lines and seven days after plating for NHDF.
2.2. Analysis of RNA and protein expression
Expression of ﬁbrillin/LTBP family members was initially examined
in cell lines using quantitative reverse transcriptase PCR from RNA
extracted from the cell lines described above. In addition RNA was
extracted from cell pellets from Day 2 of embryoid body formation
from two human ES cell lines, H1 [23] and RH1 [24] (provided respec-
tively by Professor Lesley Forester and Dr Paul De Sousa, Scottish Centre
for Regenerative Medicine, University of Edinburgh), and Day 2 of
culture of primary adipose derived mesenchymal stem cells (ADMSC)
(provided by Dr. Paul DeSousa). Total RNA was extracted from cell
lines using RNA-Bee (Amsbio, Abingdon, UK; http://www.amsbio.com/
75M.R. Davis et al. / Molecular Genetics and Metabolism 112 (2014) 73–83rna-bee.aspx). RNAwas quantiﬁed using aNanodrop spectrophotometer
and cDNAwas synthesized using MMLV reverse transcriptase (Promega
Corporation, Madison WI, USA) and an annealing temperature of 60 °C
[25]. Primers for quantitative PCR were designed using Roche primer
design (Roche Diagnostics Ltd., Burgess Hill, UK; http://www.roche-
applied-science.com, Supplementary Table 1). Human GAPDHwas used
as the reference gene (Qiagen Ltd., Crawley, UK; Hs_GAPDH_2_SG).
Quantitative PCR was performed in triplicate using LightCycler 480
SYBR Green 1 Master Mix (Roche) on the LightCycler 480 machine
(Roche). Products were quantiﬁed using software supplied by the
manufacturer.
The presence of the encoded proteins was ascertained using immu-
noﬂuorescence with a range of antibodies. 20,000 NHDF cells per well
were seeded into an eight well chamber slide (NUNC). After 7 days,
the cells were ﬁxed with 95% ethanol and 5% acetic acid for 20 min
and washed with PBS. The samples were blocked with 1% BSA in PBS
for 1.5 h prior to addition of a 1:100 dilution of the primary antibody
and incubated over night at 4 °C. Following a wash with PBS, the
secondary antibody was added at 1:1000 dilution, for 1 h at room tem-
perature. The cells were then washed with PBS, and mounted with
ProGold + DAPI (Invitrogen). Samples were viewed using Zeiss LSM
710 confocal microscope and analyzed with ZEN software at standard
settings (Zeiss). Details of antibodies used are supplied in Supplementary
Table 1.
2.3. Identiﬁcation of promoter and enhancer sequences
The tissues and cells used for the FANTOM5 analysis of transcrip-
tion initiation sites have been described in a parallel publication [16].
Brieﬂy, promoters were identiﬁed using CAGE (cap analysis of gene
expression) followed by Helicos high throughput sequencing [12,16,26].
Decomposition-based peak identiﬁcation (DPI; [16]) was used to identify
a set of transcription start sites (TSS), at permissive and robust levels
(containing at least one nucleotide position with N2 or N10 independent
singlemolecule observations respectively in a single library) [16]. Expres-
sion levels were determined using RLE normalized counts of CAGE tags
mapping to each promoter region [16]. Promoters were then numbered
by expression rank at the permissive level [16], so p1@GENE had the
highest expression of all promoters associated with that gene, followed
by p2@GENE etc. At the more stringent robust level some of these
promoters were lost and this accounts for gaps in the numbering of
robust promoters. The full permissive set can be seen on the ZENBU
browser [27] (http://fantom.gsc.riken.jp/zenbu/). Composite promoters
are those where two or more robust peaks occur within 100 bp of each
other [16]. Identiﬁcation of putative enhancers was based on the pres-
ence of bidirectional CAGE tag clusters within a 400 bp window [28].
We linked enhancers and nearby promoters (within 500 bp) with corre-
lation tests using their expression levels across all FANTOM5 samples,
requiring a Benjamini–Hochberg false discovery rate of less than 10−5
[28]. We used this resource to identify the total set of robust promoters
annotated to the seven ﬁbrillin/LTPB gene family members.
2.4. Analysis of gene co-expression clusters
All 81 DPI-detected robust promoters for the seven genes were clus-
tered using Biolayout Express3D [29,30], based on CAGE-determined ex-
pression. To enter all promoters into the analysis a low cut off pair-wise
Pearson correlation coefﬁcient of 0.17 was used. Additional analysis at
higher Pearson thresholds (as outlined in the Results) was performed
to discover tightly coregulated promoters. The MCL inﬂation value
was 2.2 for all analyses.
The parallel paper [16] presents clustering of 124,090 human
robust promoters over all samples and in three subsets (primary
cells, tissues and cell lines) based on CAGE-determined expression
patterns, with Pearson correlation coefﬁcient N0.75 and MCL inﬂation
value of 2.2. These data were reanalyzed for the present paper, lookingfor coexpression of the promoters for the seven ﬁbrillin/LTBP genes
with promoters for other genes.
2.5. Identiﬁcation of transcription factor binding motifs and transcription
factor activity
We downloaded the whole-genome alignment of the human
genome with 45 other vertebrate genomes from the UCSC Genome
Browser database [31]. We retained the alignments between the
human, macaque, mouse, rat, cow, horse, dog, opossum, and chicken
genomes, and used the T-Coffee alignment tool [32] on 1000 bp
segments of the genome to optimize the alignment for the nine selected
genomes.We then ranMotEvo [33] on thesewhole-genome alignments
to predict the occurrence of transcription factor binding sites (TFBSs)
in the human genome, using a background prior probability of 0.98, a
prior for the UFE (unidentiﬁed functional element) [33] model of 200
relative to the weight matrices, a UFE motif length of 8 bp, and a
uniform background sequence probability. Motif Activity Response
Analysis (MARA) [34] was applied on these TFBS predictions to infer
the regulatory network.
3. Results
3.1. Gene and protein expression of ﬁbrilliln/LTBP family members
We used quantitative reverse transcriptase PCR (qRT-PCR) to exam-
ine expression of gene family members in cell lines including H1 and
RH1 embryonic stem cells, ADMSC mesenchymal stem cells from adi-
pose tissue, SAOS2 and MG63 osteosarcoma cell lines and NHDF ﬁbro-
blasts, (Sections 2.1 and 2.2). The results are presented in Fig. 1.
FBN1 expression was consistently high in ADMSC, NHDF and MG63
cell types but minimal in early ES cells (Fig. 1A). It was lower in
SAOS2 cells. Immunocytochemistry using monoclonal antibodies for
ﬁbrillin-1 on human ﬁbroblast cell line NHDF showed the formation of
a rich extracellular ﬁbrillar matrix (Fig. 1B). FBN2was highly expressed
early in embryoid body formation from H1 and RH1 embryonic stem
cells and in SAOS2 and NHDF cells (Fig. 1B). Immunocytochemistry
using anti-ﬁbrillin-2 antibodies showed the formation a ﬁbrillar matrix
similar to ﬁbrillin-1 (Fig. 1D). Low but detectable expression of FBN3
was present in both ES cell lines (H1 and RH1), with no expression in
the remaining cell types (Fig. 1E), consistent with a role restricted to
early development. qPCR for LTBP1 and LTBP4 RNA revealed some
expression in cells types tested (Fig. 1F and I) while LTBP2 was high in
ADMSC and NHDF with low expression in all other cell types (Fig. 1G).
LTBP3 showed similar expression patterns except that mRNA was
detectable in MG63 (Fig. 1H).
These results suggested a mesenchymal distribution of most
ﬁbrillin/LTBP gene expression. To conﬁrm this we also carried out
qPCR and immunocytochemistry on the same cell lines for COL1A1,
COL1A2, BGN and ACTA2 (Fig. 2), genes previously shown to be highly
expressed in mesenchymal cells [10]. qRT-PCR studies showed similar
expression of COL1A1 with FBN1 and LTBP2 while COL1A2 and BGN
were expressed in all mesenchymal cells examined except SAOS2
(Fig. 2). This was similar to LTBP1 except that the latter was also highly
expressed in SAOS2. The smooth muscle actin gene ACTA2, was highly
expressed in NHDF and SAOS2 (Fig. 2D). We have previously shown
high expression of this gene in a range of mesenchymal cell types
[10,35]. Immunocytochemistry showed positive staining of the ﬁbro-
blast cell line for collagen type1, although the protein remained intra-
cellular (Fig. 2C), which was also seen previously for collagen 1
staining of osteosarcoma cell line MG63 [22]. Consistent with the RNA
expression pattern, immunocytochemistry revealed strong staining for
biglycan in NHDF cells (Fig. 2E). Positive intracellular staining of NHDF
cells for smooth muscle actin was seen (Fig. 2G). These results conﬁrm
the coexpression of ﬁbrillin/LTBP family members with mesenchymal
cell markers.
Fig. 1. Expression of ﬁbrillin/LTBP gene family members. qPCR was performed on RNA from cell lines SAOS2, MG63, H1 human embryonic stem cells and RH1 human embryonic
stem cells and from primary cells ADMSC and NHDF. Results were normalized using GAPDH. FBN3was detected solely in H1 and RH1 embryonic stem cells. See Methods for more
details. (A. FBN1; C. FBN2; E. FBN3; F. LTBP1; G. LTBP2; H. LTBP3; I. LTBP4). Fluorescent immunocytochemistry was performed on Day 7 cultured human ﬁbroblasts, NHDF. Anti-
body information is available in Supplementary Table 1. (B. ﬁbrillin-1; D. ﬁbrillin-2).
Fig. 2. Expression of mesenchymal marker genes. qPCR was performed on RNA from cell lines SAOS2, MG63, H1 human embryonic stem cells and RH1 human embryonic stem cells and
from primary cells ADMSC and NHDF. Results were normalized using GAPDH. See methods for more details. (A. COL1A1; B. COL1A2; D. BGN; F. ACTA2). Fluorescent immunocytochemistry
was performed on Day 7 cultured human ﬁbroblasts, NHDF. Antibody information is available in Supplementary Table 1. (C. collagen type 1; E. biglycan; G. smooth muscle actin).
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Fig. 3. Architecture of the human FBN1 gene. Promoters were numbered using the permissive [16] set, based on expression, with p1@FBN1 as the highest expressing promoter. Images
derived from the ZENBU browser (http://fantom.gsc.riken.jp/zenbu/) and from the USCS Genome Browser (http://genome.ucsc.edu/). Images for the other gene family members are
available in the Supplementary Figure or by accessing the ZENBU browser. A. The whole of the FBN1 gene, showing the physical location, exon/intron structure (introns —horizontal
lines; exons—vertical lines), robust promoters, CpG islands, and enhancers. Boxed area shows the region enlarged in C. B. Regulatory elements detected for FBN1 by the ENCODE Project
[36], showing trimethylation of lysine 4 in Histone 3 (H3K4Me3), DNase I hypersensitivity sites and transcription factor binding sites detected by chromatin immunoprecipitation and
sequencing. The FBN1 gene is aligned to the image in A. C. Enlargement of the region containing the promoters for FBN1, showing the consensus gene start site (Entrez gene), the start
sites of known transcripts, the CpG island and the promoters in this region.
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To assess further the tissue distribution and regulation of gene
family members, we used FANTOM5 CAGE-based data for promoter ex-
pression. There were between 1 (FBN3) and 21 (LTBP2) robust pro-
moters peaks associated with members of the gene family. Fig. 3 shows
the location and architecture of the promoters for FBN1 along with regu-
latory elements detected by the ENCODE project [36]: trimethylation of
the lysine at position 4 of histone 3 (H3K4Me3), DNase I hypersensitivity
sites and chromatin immunoprecipitation results for transcription
factors. The same data for promoters of all family members are shown
in the Supplementary Figure.
Almost all the promoters were broad promoters in CpG islands
and there were no TATA box promoters (Supplementary Figure and
Supplementary Table 2). The majority of robust peaks were within
100 bp of another peak, forming 18 composite promoters [16] across
the gene family (Supplementary Table 2). The frequency of singleton
peaks was signiﬁcantly lower than the 42% seen across the whole
human genome [16] (18/81; Χ21 = 13.0; p = 0.0003) and this was
attributable to LTBP1 (0/11 singletons; Χ21 = 7.9; p = 0.005), LTBP2
(2/21 singletons; Χ21 = 9.1; p = 0.0025) and FBN2 (1/10 singletons;
Χ21 = 4.2; p = 0.04).
There were known transcripts (RefSeq, Ensembl ENST number etc.)
starting in the region of the majority of the detected promoters, and
most known alternative transcripts were supported by this analysis(Supplementary Table 2). Notably, promoters for the three alternative
ﬁrst exons of FBN1 [37,38] were detected (Fig. 3). The vast majority of
FBN1 CAGE tags localized to the main composite promoter region con-
taining p1@FBN1 (Exon A), but p11@FBN1 is probably associated with
the rarely used Exon B of previous reports [37,38], while promoters
p7@FBN1 and p25@FBN1 may be associated with the previously de-
scribed Exon C [38] (Fig. 3B). p14@FBN2 and p18@FBN2, found in intron
25 of FBN2 (Supplementary Figure: FBN2 A. —red box and D.), were as-
sociated with the short transcript ENST00000507835.1. Two promoters
were identiﬁed in the 3′ noncoding region of the LTBP2 gene (p12@
LTBP2 and p27@LTBP2; Supplementary Figure: LTBP2 A. —red box).
They may be associated with a short overlapping transcript from
LOC730019.
Some published transcripts were not supported by CAGE tags. For
example, there was no support at the robust level for a promoter for
the long FBN2 transcript ENST00000508053.1 which has an additional
six 5′ non-coding exons (data not shown; available at http://fantom.
gsc.riken.jp/zenbu/), nor were there promoters for two long transcripts
(AY203940 and AK022050) which overlap FBN3. Similarly there was
no evidence for a promoter for the longest reported LTBP4 transcript,
NM_003573 (Supplementary Figure: LTBP4 A. —ENST00000545697
and ENST00000204005).
Transcription start sites were also detected where there was no
identiﬁed transcript. For instance, at the 5′ end of LTBP1, alternate tran-
scripts with a long or short 5′ UTR have been reported (Supplementary
Table 1
Expression levels for the highest expressing promoters of ﬁbrillin/LTBP family members.
Promoter
name
RLE normalized
expression value
Cell type
p1@FBN1 2562 Smooth muscle cells (aorta)
2496 Fibroblast (aortic adventitia)
1437 Fibroblast (skin)
1407 Sertoli cells
1358 Preadipocyte (breast)
p1@FBN2 1547 Cell line: HEPM (derived from normal human
embryonic palatal mesenchyme)
1002 Fibroblast (skin)
994 Cell line: HTST (derived from a human
sacrococcigeal teratoma)
768 Hair follicle outer root sheath cells
753 Cell line: H-EMC-SS
(derived from a human myxoid chondrosarcoma)
p2@FBN3 6 Occipital lobe (fetal)
5 Cell line: SK-N-MC (derived from a human
neuroepithelioma)
4 H9 embryonic stem cells
3 H9 embryonic stem cells
3 H9 embryoid body cells
p1@LTBP1 1903 Chondrocyte, redifferentiated
1365 Chondrocyte, redifferentiated
1278 Mesenchymal precursor cell from bone marrow
1107 Fibroblast (aortic adventitia)
1051 Smooth muscle cells (aorta)
p1@LTBP2 190 Aorta (adult pooled)
186 Dura mater (adult)
152 Preadipocyte (breast)
143 Chondrocyte, redifferentiated
136 Cell line: Hs 132
(derived from a human spindle cell sarcoma)
p1@LTBP3 391 Fibroblast (aortic adventitial)
332 Mesenchymal stem cells (adipose)
295 Smooth muscle cells (aorta)
246 Cardiac myocyte
244 Aorta (adult pooled)
p1@LTBP4 391 Aorta (adult pooled)
382 Mitral valve (adult heart)
380 Cervix, adult
260 Prostate (adult)
250 Tricuspid valve (adult heart)
Expression values are RLE normalized tags per million [16].
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script with the shorter UTR (ENST00000354476.3). Instead, a small
TSS cluster was detected midway between the main (long) start site
about 200 bp upstream of the annotated beginning of the putative
shorter transcript, which may indicate that the shorter transcript is
incomplete. Similarly a number of identiﬁed TSS in LTBP3 did not corre-
late with known transcripts (for example, see Supplementary Figure:
LTBP3 D. and E.).
Althoughmost promoterswere located in CpG islands, therewas little
conservation of sequence around the promoters. Many of the promoter
regions themselves were pyrimidine-rich (on the coding strand). The
coding strand of themain FBN1 promoter region contained a characteris-
tic pyrimidine (T-rich) stretch, about 70 nucleotides upstreamof the tran-
scription start site associated with p1@FBN1 [15,37,39]. The main FBN2
promoterwas in a C-rich regionbut thepromoter regionof the alternative
transcript (p14@FBN2 and p18@FBN2) was not in a CpG island and was
AT rich. The FBN3 promoter was also pyrimidine rich but shared no se-
quence homology with the other genes. The region around p1@LTBP1
contained alternating strings of purines and of pyrimidines.
The major promoters were all supported by regulatory elements
detected in the ENCODE project [36] (Fig. 3, Supplementary Figure:
panel B for each gene). Where regulatory elements were not detected
this may result from lack of expression in the cell types used in the
ENCODE project. For example, there are no ENCODE elements for the
composite promoter containing p14@FBN2 and p18@FBN2 (Supple-
mentary Figure: FBN2 A. —red box compared with B.), which is almost
exclusively expressed in testis, a tissue type not represented in the cell
lines examined in the ENCODE Project.
3.3. Enhancers correlated with promoters of the ﬁbrillin/LTBP gene family
Expression correlation tests, using pairs of expression peaks within
500 kb of each other (Section 2.3), predicted between four and 10 en-
hancers for the genes, with one to seven predicted enhancers per pro-
moter (Supplementary Table 3). Putative enhancers were located as
close as 2 kb up- or downstream of the promoter region. There was
no signiﬁcantly associated possible enhancer activity for the most 5′
promoters of LTBP1 (p3@LTBP1, p7@LTBP1, p8@LTBP1, p9@LTBP1,
p10@LTBP1 and p15@LTBP1). Promoters within a compound promoter
were associated with the same predicted enhancer(s) (Table 1, Supple-
mentary Tables 2 and 3). All promoters for FBN1, LTBP2 and the single
FBN3 promoter had enhancers which could be putatively linked with
the promoter by means of expression correlations (see Section 2.3),
while about half of the promoters for the other genes lacked any signif-
icant association with enhancer expression.
p7@FBN1 and p25@FBN1, initiating the alternative ﬁrst exon, Exon C
[38], were associated with different putative enhancers from p1@FBN1
and associated promoters. p14@FBN2 and p18@FBN2, in intron 25 of
FBN2, were correlated with a putative enhancer expression peak about
460 kb downstream of the promoter (Supplementary Table 3). This en-
hancer was not correlated with the other FBN2 promoters. p12@LTBP2
was uniquely associated with a bidirectional expression peak 50 kb up-
stream (Supplementary Table 3). In contrast, p10@LTBP3, p12@LTBP3
and p21@LTBP3 located within the second and third exons of the
major LTBP3 transcript were correlated with one of the same predicted
enhancers as the major promoter region containing p1@LTBP3. For
LTBP4, each promoter tended to be associatedwith a different enhancer.
3.4. Tissue speciﬁcity of promoters of ﬁbrillin/LTBP family members
The promoters all showed the characteristics of tissue restricted
expression, as deﬁned in the parallel paper [16]. Speciﬁcally, 76% of
FBN promoters and 50% of LTBP promoters had a median expression
level across the 889 cell and tissue types of 0 and for all promoters
the maximum expression was substantially greater than 10 times the
median (Supplementary Table 2).To investigate this tissue restricted expression further, we used a
number of ontologies [16] to classify the tissues and cell types with
maximum expression of the promoters (FANTOM5 SSTAR http://
fantom.gsc.riken.jp/5/sstar/ and Supplementary Table 4). Promoters in
one composite cluster within a gene tended to be expressed in tissues
associated with the same ontology terms (homogeneous composite
promoters [16]), and promoters in separate regions of the same gene
were often associatedwith different ontology terms, indicating promot-
er switches associated with cell-type speciﬁcity.
In general, the major promoters of all gene family members other
than FBN3 were strongly expressed in cells associated with ontology
terms indicating mesenchymal origin (Table 1, Supplementary
Table 4). The strongest promoters of FBN1, p1@FBN1 and p2@FBN1,
were highly expressed in cells of the same ontology terms (including
ﬁbroblast, mesodermal cell, dense mesenchyme tissue and a number of
muscle-related terms) (Supplementary Table 4). Similar ontology
termswere found for themain promoters of FBN2, whichwas expressed
in a range of cells from fetal and embryonic tissues, ﬁbroblasts, osteo-
blasts, placenta, hair follicle and lens epithelial cells (Table 1). p2@
LTBP4 shared many terms with FBN1 and FBN2 (for example, ﬁbroblast,
muscle cell, myoblast) (Supplementary Table 4). The main composite
promoter region of LTBP1 (containing p1@LTBP1; Supplementary
Figure: LTBP1 C.) was highly expressed in adult heart samples and
also expressed in tissue and cells types of mesenchymal origin. This
composite promoter was associated with mesenchyme ontology
terms including ﬁbroblast but also with many muscle related terms
Fig. 4. Coexpression of promoters of the ﬁbrillin/LTBP gene family. Colored spheres
(nodes) represent different promoters and the lines between them show correlated
expression patterns at the threshold indicated. Spheres of the same color form a
coexpression cluster of promoters with expression more similar to each other than to
the other promoters in the analysis. Promoters within each of the clusters are listed in
Supplementary Table 2. A. Clustering of expression pattern at low correlation coefﬁcient
threshold (0.17) using Biolayout Express3D. All 81 promoters were included. Genes
whose promoters are within the different colored clusters are shown in the legend. p2@
FBN3 (circled in red) clustered with p11@LTBP3, p1@LTBP4, p9@LTBP4 and p13@LTBP4.
B. Clustering at moderate correlation coefﬁcient threshold (0.50). Seventy promoters
were included. Genes whose promoters are within the different colored clusters are
shown on the ﬁgure. Promoters for most genes formed separate clusters, except that
p6@LTBP1 (circled in red) grouped with FBN1 promoters. Two LTBP3 clusters and three
LTBP4 clusters formed separate closely related groups (circled in black), although there
were also other distinct clusters containing promoters for these genes. C. Clustering at
high correlation coefﬁcient threshold (0.75). Twenty-ﬁve promoters were included.
Genes whose promoters are within the different colored clusters are shown on the ﬁgure.
Promoters for all genes formed separate clusterswith four distinct but closely related clus-
ters (circled in black) for LTBP2.
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LTBP2were associatedwith some genericmesenchymal ontology terms
(such as ﬁbroblast andmyoblast), the high expression levels in cardio-
vascular cell types also led to a preponderance of terms associated
with the vasculature (vascular associated smooth muscle cell, vascular
system, blood vessel, vascular cord) (Supplementary Table 4).
A number of promoters were expressed in tissues of other origins.
Thus p7@FBN1 and p1@LTBP3 were enriched in ontology terms
reﬂecting development of the nervous system (presumptive neural
plate, neural tube, neural rod, structure with developmental contribution
from neural crest, future spinal cord) (Supplementary Table 4). p3@
FBN2 peaked in hematopoietic cell types, and was associated with
ontology terms such as classical monocyte as well as terms reﬂecting
mesenchyme/mesoderm expression (Supplementary Table 4). p2@
LTBP2 was also expressed in some hematopoietic cells while p3@
LTBP4 was associated with lymphocytes of the immune system
(ontology terms mature alpha-beta T cell, immature T cell) but also
with terms associated with other organs (craniocervical region, skin of
body, surface structure). p7@LTBP2 demonstrated signiﬁcant expression
levels in both hematopoietic and epithelial samples and was enriched
for terms reﬂecting this expression pattern (endoepithelial cell, epithelial
cell) (Supplementary Table 4). The high expression promoter of LTBP4,
p1@LTBP4, was enriched in ontology terms reﬂecting an endodermal
origin. p14@FBN2 and p18@FBN2, located in intron 25, (Supplementary
Figure) displayed highest expression in testis and both promoters
were associated with ontology terms such as testis, male reproductive
organ, gonad and external genitalia/reproductive organ (Supplementary
Table 4).
Some promoters were associated with early development. The sole
robust promoter for FBN3, p2@FBN3, was almost exclusively expressed
in cells of fetal and embryonic origin. This expression pattern was asso-
ciated with ontology terms such as embryonic stem cell, neuronal stem
cell, neuroectodermal cell aswell as some terms relating to pigmentation
(melanocyte, melanoblast and pigment cell) (Supplementary Table 4l).
Promoters of LTBP1 leading to the longer transcript (Supplementary
Figure) were highly expressed in embryonic and extraembryonic cell/
tissue types including chorionic and amniotic membrane cells, fetal
heart, epithelial and endothelial tissue samples. Within this region,
p3@LTBP1 had the highest activity, and transcription from this region
was found primarily in fetal heart. It was most strongly associated
with ontology terms such as extraembryonic cell/structure,mesenchyme,
compound organ andmembranous layer (Supplementary Table 4).
Variability of promoter use in different cell types was supported by
the H3K4Me3 track from the ENCODE data (Supplementary Figure),
where different colored peaks (representing trimethylation levels in
different cell types) can be seen for different promoters. For example,
the composite LTBP1 promoter containing p1@LTBP1 showed strong
trimethylation of H3K4 in human lung ﬁbroblasts (NHLF), while the
composite promoter containing p3@LTBP1 was strongly trimethylated
in most of the cell lines, except embryonic stem cells and a human
lymphoblastoid cell line (Gm12878) (Supplementary Figure: LTBP1 B.).
3.5. Coexpression of ﬁbrillin/LTBP family members
To explore further the similarities and differences in promoter
expression across the gene family, we used RLE-normalized tag counts
[16] to analyze the level of expression of promoters for all seven gene
family members across the 889 RNA samples from human tissues,
primary cells and cell lines previously described [16] (data available in
Supplementary Table 2). CAGE-determined expression levels for each
of the 81 promoters were entered into Biolayout Express3D. Biolayout
Express3D employs a statistical approach to look at transcript-to-
transcript similarities in expression pattern across the samples ana-
lyzed, by calculation of a Pearson pairwise correlation matrix [29,30].
To enter all promoters into the analysis, a very low Pearson correlation
coefﬁcient threshold of 0.17 was used initially. Fig. 4A shows eachpromoter as a node (sphere) and the edges (lines) between them repre-
sent pairwise Pearson correlation coefﬁcients of ≥0.17. All LTBP2 pro-
moters formed a separate cluster (Cluster 1) with no edges to
promoters for any of the other genes, even at this low correlation
level. This indicates that the LTBP2 promoters are more similar in ex-
pression pattern to each other than to any other promoters. FBN2 pro-
moters formed two separate clusters (Clusters 3 and 11) and LTBP1
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patterns of expression for these genes. In contrast, at this low level of
correlation LTBP3 and LTBP4 promoters were frequently in the same
cluster (Clusters 5 and 7), or associated with the single FBN3 promoter
(Cluster 6), showing that these promoters share some similarity of ex-
pression pattern. Some LTBP3 and LTBP4 promoters formed separate
distinct clusters (Cluster 12 and Clusters 9 and 10 respectively). One
LTBP1 and six LTBP3 promoters also clustered with the FBN1 promoters
(Cluster 2).
At a Pearson correlation coefﬁcient threshold of 0.5, 11 promoters
were excluded from the analysis indicating that their expression pattern
was sufﬁciently different from any other promoter that they did not
correlate at this level. The sole FBN3 promoter, p2@FBN3, was in this
excluded group as were a promoter for FBN2 and LTBP1, seven for
LTBP3 and two for LTBP4. Nine of these 11 were singleton promoters
while two were within a composite promoter. The network of associa-
tions at P ≥ 0.5 is shown in Fig. 4B. All LTBP2 promoters continued
to cluster together (Cluster 1) while FBN1 (Clusters 2 and 12), FBN2
(Clusters 3 and 11) and LTBP1 (Clusters 4 and 6) formed two clusters
each. p6@LTBP1 clustered with the majority of the FBN1 promoters,
indicating an expression pattern more similar to FBN1 than to the
other LTBP1 promoters. p7@FBN1 and p25@FBN1, initiating the alterna-
tive ﬁrst exon, Exon C [38] clustered separately from the other FBN1
promoters. LTBP3 (Clusters 5, 9, 13 and 15) and LTBP4 (Clusters 7, 8,
10 and 14) formed four clusters each. These results suggest that the
most diverse expression patterns were found for promoters of LTBP3
and LTBP4, while LTBP2 had the most similar expression pattern across
all promoters.
The grouping of the promoters was also assessed at a Pearson corre-
lation threshold of 0.75. At this level, only 25 promoters were included
in the analysis, indicating that the expression of the majority did not
correlate with any other at a correlation coefﬁcient of ≥0.75. The re-
maining tight clusters consisted of four clusters of LTBP2 promoters
and single clusters for FBN1, LTPB1 and LTBP4 (Fig. 4C).
3.6. Identiﬁcation of genes co-expressed with promoters for ﬁbrillin/LTBP
family members
The results in Sections 3.1, 3.4 and 3.5 established that the ﬁbrillin/
LTBP gene family members tend to be expressed in cells of mesenchy-
mal origin, although some promoters were associated with expression
in diverse other cell types. To obtain further insight into the variability
of expression patterns, we analyzed coexpression with the full set of
promoters determined by CAGE, performed for the previous study
[16], which presented a network of 4664 coexpression groups derived
from expression proﬁles of 182,000 promoters across 887 primary cell
types, tissues and cancer cell lines (Fig. 7 in [16]). The analysis was
performed both for the entire sample and for the subsets of tissues,
cell lines and primary cells. This enabled us to identify promoters that
were co-expressed with members of the ﬁbrillin/LTBP gene family
(data shown in Supplementary Table 2).
Overall, promoters for the gene family members tended to cluster
with promoters for genes such as ACTA2, BGN, CALU, CCDC80, COL1A1,
COL1A2, COL3A1 COL4A1, COL5A1, COL6A1, COL7A1, COL17A1, COL21A1,
DCN, ELN, FBLN2, FBLN5, FN1, LOXL3, PCOLCE, POSTN, SOST, SPARC,
TGFB1, TGFBR3 and THBS1 which have previously been identiﬁed to be
expressed in mesenchymal cell types [10]. However, many promoters
failed to cluster, or clustered only with other promoters for the same
gene, indicating distinctive expression patterns that were not shared
by other genes.
p1@FBN1, p2@FBN1, p3@FBN1 and p9@FBN1 tended to cluster to-
gether with a small number of other promoters such as promoters for
CALU and CCDC80. In contrast, the promoters associated with the alter-
native exon C, p7@FBN1 and p25@FBN1 clustered with promoters for
neurally expressed genes. Similarly the promoters for the short testis
speciﬁc FBN2 transcript, p14@FBN2 and p18@FBN2, clustered togetherwith testis speciﬁc and connective tissue genes; the remaining FBN2
promoters frequently failed to cluster. p2@FBN3 was found in large
clusters of promoters for genes involved in regulating development
including NANOG, FOXG1, FOXO6, FOXP1, PRICKLE1 and SOX14 as well
as neural genes such as potassium channels andMAPT and connective
tissue genes including COL9A1, COL9A3, ACTA1 and ACTN3.
Promoters for LTBP genes tended to fail to cluster or formed clusters
with other promoters for the same gene, particularly in the primary cell
analysis. p1@LTBP1, p2@LTBP1, p4@LTBP1 and p5@LTBP1 formed a
small cluster when all samples were analyzed and p3@LTBP1, p7@
LTBP1 and p8@LTBP1 formed a cluster when primary cells were ana-
lyzed (Supplementary Table 2). However some LTBP promoters clus-
tered with promoters for mesenchymal genes and occasionally were
foundwith promoters for othermembers of theﬁbrillin/LTBP gene fam-
ily. LTBP3 promoters usually failed to cluster, even with each other. The
coexpression analysis for LTBP4 promoters consistently grouped p2@
LTBP4, p6@LTBP4 and p7@LTBP4 in clusters containing only these pro-
moters (Supplementary Table 2).
3.7. Transcription factors regulating ﬁbrillin/LTBP gene family members
We used Motif Activity Response Analysis (MARA) [34] to infer
the regulatory network of transcription factor motifs in 47 promoters
of theﬁbrillin/LTBP gene family (Supplementary Table 2).Motifs associ-
ated with the MAZ, SP1, GTF2I and KLF4 transcription factors were
found to regulate 16 to 20 promoters. For FBN1 (seven regulated pro-
moters in total), the motifs for GTF2I, NKX3-1, TBX4-5 and TFAP4 regu-
lated ﬁve promoters, while for FBN2 (6 promoters) HIF1A was found to
regulate four promoters and TFDP1, KLF4, TFAP2B and TOPORS regulat-
ed three promoters. Therewere no signiﬁcant regulatory edges for FBN3
(Supplementary Table 2). However, bindingmotifs for the transcription
factors MAZ, PATZ1, RREB1, SP1 and TFAP4 were detected in the pro-
moter region of FBN3.
LTBP1 (regulated at nine promoters in total) and LTBP2 (regulated at
16 promoters) showed signiﬁcant regulation by theMAZmotif in seven
and eight promoters respectively. Five promoters of LTBP1 were also
regulated by HIC1 and NFY while four promoters were regulated by
PRDM1, RXR and SOX 17. LTBP2 was predicted to be regulated by
KLF4 (at 10 promoters), SP1 (at eight promoters), GATA4 and TEAD
(at ﬁve promoters) and XCPE1 (at four promoters) was associated
with LTBP2. Regulation at seven LTBP3 promoters was detected, through
motifs for GTF2I and SP1 (at six promoters), MED-1 (at ﬁve promoters)
and TFAP2 and ZFP161 (at four promoters). Only two LTBP4 promoters
were signiﬁcantly associated with motifs, with TRAF2B found for both
(Supplementary Table 2).
4. Discussion
Members of theﬁbrillin/LTBP gene family appear to play two roles in
the extracellular matrix. Firstly, they contribute structurally to the for-
mation of the matrix. In particular, ﬁbrillin-1 and ﬁbrillin-2 are integral
components of the 10 nmmicroﬁbrils which provide strength and elas-
ticity to the matrix [40,41]. Secondly, they are instrumental in regulat-
ing the bioavailability of members of the TGFβ superfamily of growth
factors [6]. While some ﬁbrillin/LTBP family members (ﬁbrillin-1,
ﬁbrillin-2 and LTBP2) do not appear to bind TGFβ molecules directly,
they interact with other members of the family that do bind to these
growth factors. The TGFβ superfamily contains 33 proteins [42,43] and
it is possible that ﬁbrillin/LTBP family members bind directly to other
TGFβ-like molecules such as bone morphogenic proteins (BMPs) and
activins/inhibins. TGFβ activation requires the action of force on the
TGFβ prodomain, and this may be exerted via ﬁbrillins reacting to per-
turbations of the ECM [44]. Therefore these proteins are an important
component of the extracellularmatrix both inmaintaining the structural
integrity of the matrix and in controlling the growth and differentiation
of the cells they surround. Their overlapping roles raise the possibility
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some resilience to inactivating mutations in family members.
In this study we have examined gene expression and regulation
of the seven ﬁbrillin/LTBP family members using results from the
FANTOM5 CAGE analysis, a genome wide analysis of transcription
start sites and bidirectional putative enhancers [16,28]. We have dem-
onstrated the predominant expression of this gene family in
mesenchyme-derived cells and tissues. It is also clear that some gene
family members are required in early development, in neural tissue
and the cardiovascular system. Expression derived from CAGE tag
analysis was conﬁrmed for a number of mesenchymal and embryonic
stem cell lines using quantitative reverse transcriptase PCR and
immunocytochemistry.
Thereweremultiple examples of differential use of promoters in dif-
ferent tissue types (promoter switching) and this was frequently asso-
ciated with differences in ENDOCE regulatory elements and distinctive
predicted enhancer activity. The main promoter region of FBN1 was
highly expressed in a range of connective tissue cells, consistent with
previously published transcription factor activity [10,15,37] but p7@
FBN1 expressionwas predominantly found in neural cell types enriched
in ontology terms related to neural development, clustered with other
neural-associated genes and was associated with a unique enhancer.
This promoter showed regulation by FOXD3 (Supplementary Table 2)
a transcriptional regulator essential for progenitor cells and found
mainly within the embryonic neural crest [45].
Promoter switching with a change in tissue speciﬁcity was also seen
for FBN2, where p14@FBN2 and p18@FBN2 were expressed in repro-
ductive cell types. The transcript associated with these promoters,
ENST00000507835.1, covers coding exons 26 to 34 of the full length
FBN2 and the polypeptide would consist of eight cbEGF domains with
short N- and C-terminal ﬂanking sequences (http://www.ensembl.
org). Preliminary examination of the mouse CAGE data from FANTOM5
showed an equivalent promoter exclusively expressed in mouse testis,
suggesting that this transcript has a real function, perhaps involved
with sequestration of calcium. Further investigation of this novel tran-
script should reveal more about its role.
LTBP1 is documented to have at least two alternative transcription
start regions (http//:www.ensembl.org) and this switch in promoters
was conﬁrmed in our analysis. One promoter region demonstrated
high expression in early development and low expression inmesenchy-
mal cells (p10@LTBP1, p8@LTBP1, p9@LTBP1, p3@LTBP1, p15@LTBP1
and p7@LTBP1) while the alternate promoter region (p6@LTBP1, p2@
LTBP1, p1@LTBP1,p5@LTBP1 and p4@LTBP1) was associated with
mesenchyme-related ontology terms and expressed in heart. The
major promoters p1@LTBP1 and p2@LTBP1 were associated with the
same transcription factor motifs (LHX, GTF2I, PRDM1, SOX17), while
the alternative promoter region was associated with a distinct set of
transcription factors motifs (including HIC1, NFY, NR1H4).
Putative enhancers within 500 kb of the promoter regions were sig-
niﬁcantly associatedwithmany of the promoters examined. Themajor-
ity were downstream of the promoter region and some were as close
2 kb from the promoter. In general many promoters in one gene were
correlated with the same predicted enhancers although there were a
few examples of promoter-speciﬁc enhancers, associated with pro-
moters of unique expression pattern.
Cluster analysis of expression from thedifferent promoters highlight-
ed the differences between the gene family members. Members of
a composite promoter often clustered together, but few promoters for
different genes were found in the same cluster. For example, most pro-
moters for FBN2 showed similar expression patterns and ontology term
enrichment to FBN1. However, FBN1 and FBN2 promoters did not cluster
together in the co-expression analyses and there was little overlap of
transcription factor motif activity between FBN1 and FBN2 promoters,
suggesting that therewere subtle differences in their expression patterns
and regulation. In particular, FBN2 promoters tended to be associated
with the epithelial and pluripotency transcription factor KLF4 [46]and other stem cell associated factors TFAP2B [47] and PAX5 [48,49]
consistent with a requirement for ﬁbrillin-2 in early development. In
contrast, FBN1 promoters were associated with mesenchymal transcrip-
tion factors [10].
Although there was no transcription factor that was associated with
all family members, there was apparent regulation across the group
through a number of transcription factor motifs including those for
MAZ, SP1, GTF2I and KLF4. Regulation through transcription factor
motifs reﬂecting tissue speciﬁcity was also found. The group of pro-
moters between p1@LTBP2 and p15@LTBP2 (Supplementary Figure:
LTBP2 A —blue box and C.), for example, showed signiﬁcant potential
to bind GATA4 (associated with cardiac differentiation [50,51]) and
MYOD (myogenic differentiation; reviewed in [52]). FANTOM5 data
for these promoters showed highest expression in aortic smoothmuscle
cells, and various other mesenchyme speciﬁc tissue and cell types.
Because its expression is restricted to fetal and embryonic tissue
types [9], the promoter of FBN3 could not be determined from the
earlier FANTOM3 data which lacked samples from relevant human
cells. FANTOM5 has a much greater representation of human cells
and tissues from early developmental stages and we have now iden-
tiﬁed the promoter region and the most common starting nucleotide
for human FBN3. We have conﬁrmed that ﬁbrililn-3 is expressed in
early development and neural tissues of humans [9]. Since Fbn3 is in-
active in mouse and rats [9], it is possible that one of the other gene
family members substitutes for its function. Since transcription fac-
tor binding motifs found in the promoter region of FBN3 overlap
with those of LTBP genes but not ﬁbrillin genes, it is conceivable
that its role is taken by one of the LTBPs. From our analysis possible
candidates based on expression pattern in human embryonic cell
types would be Ltbp1 (through p3@LTBP1) or Ltbp4 (through p5@
LTBP4). Preliminary analysis of FANTOM5 data for mouse indicates
that the equivalent of p3@LTBP1 is strongly expressed in embryonic
tissue, especially neuron derived neurospheres, while a region
equivalent to p5@LTBP4 is expressed in embryonic stem cells (data
not shown; available at FANTOM5 website http://fantom.gsc.riken.
jp/5/), supporting this possibility.
Mutations in human FBN1, FBN2, LTBP2, LTBP3 and LTBP4 have been
associated with connective tissue disease in humans. Transgenic and
natural mutation mouse models, available for Fbn1, Fbn2, Ltbp1, Ltbp2,
Ltbp3 and Ltbp4 also show phenotypic abnormalities of connective tis-
sue (reviewed in [7]), consistent with the predominant expression in
mesenchymal cells of these genes. Further analysis of gene familymem-
bers for genetic variation which affects the different promoter regions
may reveal a role in more subtle connective tissue phenotypes. In addi-
tion, examination of promoter usage in relevant tissues in the presence
of these mutations may reveal whether the severity of the phenotype is
modiﬁed by changes in expression of gene family members, indicating
a degree of redundancy. Because of similarities in structure and ex-
pression patterns, upregulation of ﬁbrillin/LTBP family members may
provide a possible therapeutic approach for these connective tissue
conditions.5. Conclusions
This study supports the differential roles of members of the ﬁbrillin/
LTBP gene family. We have shown the strong mesenchymal expression
ofmost familymembers andmost promoters and highlighted promoter
and enhancer switching associated with changes in tissue speciﬁcity.
We were unable to ﬁnd evidence for a single “master mesenchyme
regulator” but therewas considerable overlap in the transcription factor
activity associated with these genes. These data aid in better under-
standing the overall function and activity of the members of the
ﬁbrillin/LTBP family.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ymgme.2013.12.006.
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